Why the study?
Does the severity of paclitaxel-associated acute pain syndrome predict the development of chemotherapy-induced peripheral neuropathy in patients receiving paclitaxel and carboplatin?
Population
Patients about to receive paclitaxel and carboplatin every 3 weeks
Design
Cohort
Authors
Loading...
High P-APS scores may flag elevated CIPN risk; hypothesis-generating for preventive trials in paclitaxel recipients.
Does the severity of paclitaxel-associated acute pain syndrome predict the development of chemotherapy-induced peripheral neuropathy in patients receiving paclitaxel and carboplatin?
Higher severity of paclitaxel-associated acute pain syndrome is associated with a greater risk of developing chemotherapy-induced peripheral neuropathy.
Reeves et al. (2012) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: